Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.

Pharmacogenetics - 1 May 2004

Furman Katherine D, Grimm David R, Mueller Toby, Holley-Shanks Rhonda R, Bertz Richard J, Williams Laura A, Spear Brian B, Katz David A

Abstract excerpt

This study utilized cytochrome P450 2D6 (CYP2D6) genotypes to explain variability of desipramine pharmacokinetics in a cohort of non-poor metabolizer individuals. In an interaction study utilizing desipramine as a probe, genotyping for the CYP2D6*3, *4, *5 and *6 alleles was used to screen out CYP2D6 poor metabolizers. Individuals were categorized according to these and additional alleles (CYP2D6*2, *9, *10, *17,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antidepressive Agents, Tricyclic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Haplotypes

Share to Phenotype

Source

Identifiers

PMID: 15115913
DOI: 10.1097/00008571-200405000-00002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.PMID 15115913Read ↗

Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.Semantic proximity Read ↗

Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine.Semantic proximity Read ↗

Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.Semantic proximity Read ↗

Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial.Semantic proximity Read ↗

Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of Brexpiprazole.Semantic proximity Read ↗

Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.Semantic proximity Read ↗

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.Semantic proximity Read ↗

Pharmacogenetics of desipramine metabolism.Semantic proximity Read ↗

Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.Semantic proximity Read ↗

Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine.Semantic proximity Read ↗

Polymorphic 2-hydroxylation of desipramine. A population and family study.Semantic proximity Read ↗

Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.